

Contents

	Introduction	14
1.1.	References.....	15
	History of immune thrombocytopenia (ITP)	18
2.1.	Introduction: What is thrombocytopenic bleeding?	18
2.2.	History of bleeding	18
2.3.	History of the pathogenesis of ITP	20
2.4.	History of management of patients with ITP	20
2.5.	Actual progress of ITP	22
2.6.	References.....	22
	Etiology and pathophysiology of ITP	26
3.1.	The basic immunology of immune thrombocytopenia (ITP): a brief review	26
3.1.1.	Introduction	26
3.1.2.	T cell and cytokine abnormalities in ITP	26
3.1.3.	B cell abnormalities.....	27
3.1.4.	Genetic factors in ITP	27
3.1.5.	Environmental factors in ITP	27
3.1.6.	Alternative modes of B and T cell-mediated platelet destruction	28
3.1.7.	Conclusions.....	28
3.1.8.	References	29
3.2.	Thrombopoiesis and ITP	32
3.2.1.	Overview of normal Thrombopoiesis.....	32
3.2.2.	Thrombopoiesis in ITP: evidence for accelerated platelet destruction	34
3.2.3.	Thrombopoiesis in ITP: evidence for impaired platelet production	34
3.2.4.	References	35
3.3.	Platelet function in immune thrombocytopenia.....	38
3.3.1.	Introduction	38
3.3.2.	The role of platelet antibodies	38
3.3.3.	Platelet hemostasis.....	38
3.3.4.	How to assess platelet function in ITP	39
3.3.5.	Estimation of platelet function by flow cytometry	39
3.3.6.	Evaluation of platelet function in patients treated with TPO receptor agonists: experience with eltrombopag	40
3.3.7.	References	41
3.4.	Familial Immune Thrombocytopenia (ITP)	42
3.4.1.	Introduction	42
3.4.2.	Differential diagnostic considerations	43
3.4.3.	Evidence for heredity in ITP	45
3.4.4.	Discussion	46
3.4.5.	References	47
	Drugs in ITP: mechanisms of action	50
4.1.	Introduction	50
4.2.	Steroids	50
4.3.	Intravenous immunoglobulin (IVIg)	50

4.4.	Anti-D	52
4.5.	Rituximab (anti-CD20)	52
4.6.	Drugs that stimulate platelet production	53
4.7.	References	54

Standardization of definitions and terminology: a common language in ITP 58

5.1.	Introduction	58
5.2.	Methodology and criteria to harmonize terminology and definitions in ITP	59
5.3.	Primary and secondary ITP and diagnostic platelet count threshold	60
5.4.	Definition of the different phases and severity of the disease	61
5.5.	Therapeutic goals	61
5.6.	Definition of response	62
5.7.	Refractory ITP: definition, therapeutic goals and response assessment	64
5.8.	Clinical trial-adapted criteria	65
5.9.	References	66

Immune thrombocytopenia in childhood: a problem-oriented review of the management 70

6.1.	Introduction	70
6.2.	Clinical presentation and diagnosis	72
6.3.	Prevention from and therapy of bleeding	73
6.4.	Non-intervention	73
6.5.	Intervention	74
6.6.	Splenectomy	75
6.7.	Conclusions	76
6.8.	References	76

Immune thrombocytopenia in adulthood 80

7.1.	Introduction	80
7.2.	Treatment of adult ITP	80
7.2.1.	General rules	80
7.2.2.	First-line therapy (initial treatment for newly diagnosed patients)	81
7.2.3.	Second-line therapy	83
7.2.4.	Other second-line therapies	83
7.2.5.	New perspectives for second-line therapies in the management of adults with ITP	84
7.2.6.	Patients failing first- and second-line therapies	86
7.3.	References	87

Chronic refractory immune thrombocytopenia 92

8.1.	Introduction	92
8.2.	Etiology and risk factors	92
8.2.1.	Drug-induced thrombocytopenia	92
8.2.2.	Infection-related thrombocytopenia	93
8.3.	Therapeutic approach	94
8.3.1.	Observation	95
8.3.2.	Standard therapy	95
8.3.3.	Therapy for refractory disease	95

8.4.	Outcomes and sequelae	100
8.5.	References	101
	Immune thrombocytopenia in pregnancy	106
9.1.	Introduction.....	106
9.2.	The differential diagnosis of thrombocytopenia during pregnancy	106
9.3.	ITP in pregnancy.....	107
9.4.	References	109
	Future considerations of immune thrombocytopenia	112
10.1.	Heterogeneity of ITP.....	112
10.2.	Unknown etiology of ITP.....	113
10.3.	Complex pathogenesis of inflammatory and autoimmune disorders, where ITP is a model	113
10.4.	The question of adequate management of ITP.....	114
10.5.	References	115
	Index	118